Jounce Therapeutics
A clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients.
Launch date
Employees
Market cap
€89.0m
Enterprise valuation
(€74m) (Public information from May 2023)
Share price
$1.88 JNCE
Cambridge Massachusetts (HQ)
Authorizing premium user...